|
Gene: TMEM80 |
Gene summary for TMEM80 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TMEM80 | Gene ID | 283232 |
Gene name | transmembrane protein 80 | |
Gene Alias | TMEM80 | |
Cytomap | 11p15.5 | |
Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | A0A0A0MS80 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
283232 | TMEM80 | HCC1_Meng | Human | Liver | HCC | 1.17e-46 | 9.26e-04 | 0.0246 |
283232 | TMEM80 | HCC2_Meng | Human | Liver | HCC | 8.04e-09 | -1.14e-03 | 0.0107 |
283232 | TMEM80 | cirrhotic1 | Human | Liver | Cirrhotic | 6.99e-07 | 2.03e-01 | 0.0202 |
283232 | TMEM80 | cirrhotic2 | Human | Liver | Cirrhotic | 2.64e-05 | 1.27e-01 | 0.0201 |
283232 | TMEM80 | HCC1 | Human | Liver | HCC | 1.09e-02 | 2.86e+00 | 0.5336 |
283232 | TMEM80 | Pt13.b | Human | Liver | HCC | 3.22e-04 | 4.96e-02 | 0.0251 |
283232 | TMEM80 | S014 | Human | Liver | HCC | 1.98e-04 | 2.01e-01 | 0.2254 |
283232 | TMEM80 | S016 | Human | Liver | HCC | 9.70e-04 | 1.61e-01 | 0.2243 |
283232 | TMEM80 | S027 | Human | Liver | HCC | 3.09e-08 | 3.95e-01 | 0.2446 |
283232 | TMEM80 | S028 | Human | Liver | HCC | 2.44e-06 | 3.15e-01 | 0.2503 |
283232 | TMEM80 | S029 | Human | Liver | HCC | 5.69e-16 | 6.25e-01 | 0.2581 |
283232 | TMEM80 | C04 | Human | Oral cavity | OSCC | 1.44e-08 | 3.62e-01 | 0.2633 |
283232 | TMEM80 | C21 | Human | Oral cavity | OSCC | 1.18e-17 | 6.71e-01 | 0.2678 |
283232 | TMEM80 | C30 | Human | Oral cavity | OSCC | 6.28e-06 | 4.40e-01 | 0.3055 |
283232 | TMEM80 | C43 | Human | Oral cavity | OSCC | 1.21e-08 | 2.68e-01 | 0.1704 |
283232 | TMEM80 | C46 | Human | Oral cavity | OSCC | 6.60e-20 | 4.78e-01 | 0.1673 |
283232 | TMEM80 | C51 | Human | Oral cavity | OSCC | 1.35e-09 | 5.36e-01 | 0.2674 |
283232 | TMEM80 | C06 | Human | Oral cavity | OSCC | 1.33e-04 | 4.78e-01 | 0.2699 |
283232 | TMEM80 | C08 | Human | Oral cavity | OSCC | 3.37e-02 | 1.29e-01 | 0.1919 |
283232 | TMEM80 | C09 | Human | Oral cavity | OSCC | 4.67e-14 | 4.64e-01 | 0.1431 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMEM80 | SNV | Missense_Mutation | c.260N>C | p.Leu87Pro | p.L87P | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-BH-A0BT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | ||
TMEM80 | SNV | Missense_Mutation | rs754819477 | c.434N>A | p.Arg145Gln | p.R145Q | protein_coding | deleterious(0.05) | benign(0.103) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
TMEM80 | deletion | Frame_Shift_Del | novel | c.555delG | p.Leu186CysfsTer48 | p.L186Cfs*48 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | |||
TMEM80 | SNV | Missense_Mutation | rs755852416 | c.161G>A | p.Arg54Gln | p.R54Q | protein_coding | tolerated(0.14) | benign(0.062) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
TMEM80 | SNV | Missense_Mutation | c.161N>C | p.Arg54Pro | p.R54P | protein_coding | tolerated(0.07) | benign(0.307) | TCGA-HG-A2PA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Taxol | PD | ||
TMEM80 | SNV | Missense_Mutation | novel | c.266N>T | p.Ser89Leu | p.S89L | protein_coding | deleterious(0.01) | probably_damaging(0.947) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | |
TMEM80 | SNV | Missense_Mutation | rs753750484 | c.433N>T | p.Arg145Trp | p.R145W | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
TMEM80 | SNV | Missense_Mutation | c.374A>G | p.His125Arg | p.H125R | protein_coding | tolerated(0.38) | benign(0.012) | TCGA-B5-A11O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
TMEM80 | SNV | Missense_Mutation | rs753750484 | c.433N>T | p.Arg145Trp | p.R145W | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TMEM80 | SNV | Missense_Mutation | novel | c.595N>A | p.Leu199Ile | p.L199I | protein_coding | tolerated(0.07) | benign(0.155) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |